Compounded Semaglutide Safety in 2026: What the FDA Shortage Changes Mean for Patients

The story of compounded semaglutide in the United States is one of the more unusual intersections of drug policy, manufacturing law, and clinical demand in recent pharmaceutical history. Understanding where things stand in 2026 requires separating several questions that are frequently conflated: whether compounded semaglutide is legal to dispense, whether it is equivalent to brand-name semaglutide, and whether the current regulatory environment has changed the risk calculus for patients who consider using it.

How Compounding and the Shortage List Work

Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, licensed compounding pharmacies may prepare copies of approved drugs without FDA approval under specific conditions. One of those conditions is active drug shortage status. When a drug appears on FDA’s shortage list, compounders may produce it lawfully, even if the active pharmaceutical ingredient would otherwise not be permissible to compound (because it duplicates an FDA-approved product).

Semaglutide—the active molecule in Wegovy and Ozempic—appeared on FDA’s shortage list in 2022 as demand for both products dramatically exceeded Novo Nordisk’s production capacity. This shortage designation created the legal window for compounding pharmacies to produce semaglutide, which they did at significant scale.

In early 2025, FDA announced that the shortage for Wegovy (semaglutide 2.4 mg) had been resolved. This triggered a phaseout period for compounded semaglutide, with FDA issuing guidance that 503A compounders must stop producing semaglutide copies within 60 days and 503B outsourcing facilities within 90 days of the announcement. The legal landscape for compounded semaglutide as of 2026 is therefore meaningfully different from 2023 or 2024.

Safety Data: What Is and Is Not Known

Compounded semaglutide is not the same as FDA-approved Wegovy or Ozempic. The safety and efficacy data from the STEP and SCALE trial programs applies to Novo Nordisk’s proprietary semaglutide formulation, manufactured under tightly controlled conditions with specific excipients, pH buffering, and delivery system specifications. Compounded versions are produced using semaglutide base or salt purchased from third-party API suppliers, and the formulation details—concentration, pH, preservatives, diluents—vary between compounders.

FDA’s concerns about compounded semaglutide have centered on several documented issues. Dosing errors have been reported, largely attributed to the use of multi-dose vials that require patient self-measurement (in contrast to Wegovy’s fixed single-dose autoinjectors). Reports of adverse events following compounded semaglutide use have been filed with FDA’s MedWatch system, though causation is difficult to attribute in the absence of post-market surveillance data comparable to what exists for approved products.

FDA has also flagged concerns about ingredients found in some compounded formulations that are not present in the approved products, including semaglutide sodium and semaglutide acetate—salt forms of the molecule for which clinical equivalence to the free acid form used in Wegovy has not been established in peer-reviewed trials.

What Good Compounding Looks Like

Not all compounded semaglutide is equivalent in quality. 503B outsourcing facilities—which operate under FDA current Good Manufacturing Practice (cGMP) standards and are subject to FDA inspection—represent a higher standard of compounding oversight than 503A community compounders, which are regulated primarily by state pharmacy boards.

Patients who access or accessed compounded semaglutide through reputable telehealth platforms typically received medication from 503B facilities, with dosing instructions, concentration documentation, and clinical oversight from a licensed physician. Patients who purchased compounded semaglutide from online pharmacies without physician involvement, or from unverified sources, faced substantially higher risk of dosing error, contamination, or adulterated product.

The 2026 Patient Decision

For patients currently using compounded semaglutide, the core questions are whether their source is still operating within current legal parameters and whether they have physician oversight of their dosing and clinical status. Patients who began treatment through a physician-supervised telehealth program using 503B-sourced compounded semaglutide were in a meaningfully safer position than those who self-managed, and the appropriate response to the changing regulatory environment is a clinical conversation with the prescribing physician—not abrupt self-discontinuation.

Patients considering starting treatment have a narrower set of options for compounded semaglutide than existed in 2023. Brand-name Wegovy availability has improved substantially. Telehealth platforms offering physician-supervised access to Wegovy at manufacturer list price, with savings cards for eligible commercially-insured patients, now represent a more accessible path than they were during the shortage.